STM Journals Peer-reviewed research from Consortium e-Learning Network

International Journal of Toxins and Toxics Review Article

A Comprehensive Review on the Role of Antacids in the Management of Stomach Disorders

  1. Khushboo Yadav JBIT College of pharmacy, 23 Milestone, NH-07, Chakrata Rd

Abstract

Antacids are among the most widely used over-the-counter medications for the symptomatic management of acid-related gastrointestinal disorders, including dyspepsia, gastroesophageal reflux disease (GERD), gastritis, and peptic ulcer disease. These agents provide rapid relief by neutralizing gastric hydrochloric acid, thereby increasing intragastric pH and reducing mucosal irritation. In addition to their therapeutic benefits, the long-term and excessive use of antacids may be associated with adverse effects and toxicological concerns, including electrolyte imbalance, metabolic disturbances, drug interactions, and organ-specific complications. This review summarizes the classification, mechanism of action, therapeutic applications, safety profile, adverse effects, and toxicological aspects of commonly used antacids. Furthermore, the review highlights the clinical significance of rational antacid use and emphasizes the importance of monitoring potential toxicity associated with prolonged administration. Understanding both the beneficial and toxicological effects of antacids is essential for optimizing patient outcomes and ensuring safe pharmacotherapy in the management of stomach disorders.

Keywords

References (1)

  1. Feldman M, Burton ME. Histamine2-receptor antagonists and antacids in the treatment of acid-peptic disorders. N Engl J Med. 1990;323(24):1672–1680. 2. Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2013;108(3):308–328. 3. Freston JW. Long-term acid control and the role of antacids in gastrointestinal disorders. Aliment Pharmacol Ther. 2001;15(Suppl 2):48–54. 4. McCarthy DM. Adverse effects and safety considerations of antacid therapy. Gastroenterol Clin North Am. 2017;46(1):1–15. 5. Wallace JL, Sharkey KA. Pharmacotherapy of gastric acidity, peptic ulcers, and gastroesophageal reflux disease. In: Brunton LL, Hilal-Dandan R, Knollmann BC, editors. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 13th ed. New York: McGraw-Hill Education; 2018. p. 883–908. 6. Katzung BG. Basic and Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021. 7. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang and Dale's Pharmacology. 10th ed. London: Elsevier; 2023. 8. Tripathi KD. Essentials of Medical Pharmacology. 9th ed. New Delhi: Jaypee Brothers Medical Publishers; 2024. 9. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2022. 10. Dipiro JT, Yee GC, Posey LM, Haines ST, Nolin TD, Ellingrod VL. Pharmacotherapy: A Pathophysiologic Approach. 12th ed. New York: McGraw-Hill Education; 2023. 11. National Institute of Diabetes and Digestive and Kidney Diseases. Acid Reflux (GER & GERD) in Adults. Bethesda (MD): NIDDK; 2024. 12. World Health Organization. WHO Model List of Essential Medicines. Geneva: World Health Organization; 2023. 13. Malfertheiner P, Chan FKL, McColl KEL. Peptic ulcer disease. Lancet. 2009;374(9699):1449–1461. 14. Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R. The Montreal definition and classification of gastroesophageal reflux disease. Am J Gastroenterol. 2006;101(8):1900–1920. 15. Scarpignato C, Pelosini I. Review article: the opportunities and benefits of extended acid suppression. Aliment Pharmacol Ther. 2006;23(Suppl 2):23–34.